References
- JankovicJParkinson’s disease: clinical features and diagnosisJ Neurol Neurosurg Psychiatry200879436837610.1136/jnnp.2007.12495818344392
- ConnollyBSLangAEPharmacological treatment of Parkinson disease: a reviewJAMA2014311161670168310.1001/jama.2014.365424756517
- WeintraubDSiderowfADPotenzaMNAssociation of dopamine agonist use with impulse control disorders in Parkinson diseaseArch Neurol200663796997310.1001/archneur.63.7.96916831966
- Jiménez-UrbietaHGagoBde la RivaPDelgado-AlvaradoMMarinCRodriguez-OrozMCDyskinesias and impulse control disorders in Parkinson’s disease: from pathogenesis to potential therapeutic approachesNeurosci Biobehav Rev20155629431410.1016/j.neubiorev.2015.07.01026216865
- RobottomBJEfficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s diseasePatient Prefer Adherence20115576410.2147/PPA.S1118221423589
- RyuS-WKimEApoptosis induced by human Fas-associated factor 1, hFAF1, requires its ubiquitin homologous domain, but not the Fas-binding domainBiochem Biophys Res Commun200128651027103210.1006/bbrc.2001.550511527403
- BetarbetRAndersonLRGearingMFas-associated factor 1 and Parkinson’s diseaseNeurobiol Dis200831330931510.1016/j.nbd.2008.05.00618573343
- SulJ-WParkM-YShinJAccumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegenerationHum Mol Genet20132281558157310.1093/hmg/ddt00623307929
- SuhJYiKYLeeY-SKimEYumEKYooS-ESynthesis and biological evaluation of 3-substituted-benzofuran-2-carboxylic esters as a novel class of ischemic cell death inhibitorsBioorg Med Chem Lett201020226362636510.1016/j.bmcl.2010.09.10220943387
- JungSHSuhJHKimEHKimJTYooS-EKangNSThe discovery of inhibitors of Fas-mediated cell death pathway using the combined computational methodBioorg Med Chem Lett201323185155516410.1016/j.bmcl.2013.07.01823916254
- JeongJ-WYuCLeeJ-HSubacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-Parkinson’s disease agent, after oral administration in rats and dogsRegul Toxicol Pharmacol20168138739610.1016/j.yrtph.2016.09.02227664323
- FoodUSAdministrationDrugGuidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers Available from: https://www.fda.gov/downloads/drugs/guidances/ucm078932.pdfAccessed May 31, 2016
- BondALaderMThe use of analogue scales in rating subjective feelingsBr J Med Psychol19744721121810.1111/j.2044-8341.1974.tb02285.x
- McNairDLorrMDropplemanLProfile of Mood StatesSan DiegoEducational and Industrial Testing Service1971
- HwangSTKimJHParkGBKorean-Wechlser Adult Intelligence Scale-IV (KWAIS-IV)DaeguKorea Psychology Co. Ltd2011
- TysnesO-BStorsteinAEpidemiology of Parkinson’s diseaseJ Neural Transm2017124890190510.1007/s00702-017-1686-y28150045
- PardridgeWMBlood-brain barrier biology and methodologyJ Neurovirol19995655656910.3109/1355028990902128510602397
- Hammarlund-UdenaesMThe use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepilepticsAdv Drug Deliv Rev2000452–328329410.1016/S0169-409X(00)00109-511108980
- ZlokovicBVThe blood-brain barrier in health and chronic neurodegenerative disordersNeuron200857217820110.1016/j.neuron.2007.12.02718215617
- BartelsALWillemsenATKortekaasRDecreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSAJ Neural Transm200811571001100910.1007/s00702-008-0030-y18265929
- KortekaasRLeendersKLvan OostromJCHBlood–brain barrier dysfunction in Parkinsonian midbrain in vivoAnn Neurol200557217617910.1002/ana.2036915668963